BridgeBio Pharma - BBIO Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $47.17
  • Forecasted Upside: 75.80%
  • Number of Analysts: 11
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$26.83
▼ -1.53 (-5.39%)

This chart shows the closing price for BBIO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BridgeBio Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BBIO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BBIO

Analyst Price Target is $47.17
▲ +75.80% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for BridgeBio Pharma in the last 3 months. The average price target is $47.17, with a high forecast of $70.00 and a low forecast of $33.00. The average price target represents a 75.80% upside from the last price of $26.83.

This chart shows the closing price for BBIO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 11 polled investment analysts is to moderate buy stock in BridgeBio Pharma. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/21/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/19/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/19/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/18/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/16/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/14/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/14/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/13/2024

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/21/2024Raymond JamesInitiated CoverageOutperform$45.00Low
3/20/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$35.00 ➝ $45.00Low
3/19/2024Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$60.00 ➝ $70.00Low
3/5/2024MizuhoLower TargetBuy ➝ Buy$60.00 ➝ $53.00Low
3/4/2024HC WainwrightReiterated RatingBuy ➝ Buy$47.00Low
2/23/2024CitigroupBoost TargetBuy ➝ Buy$42.00 ➝ $46.00Low
1/31/2024BMO Capital MarketsInitiated CoverageMarket Perform$37.00Low
1/29/2024HC WainwrightBoost TargetBuy ➝ Buy$22.00 ➝ $47.00Low
1/22/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$50.00Low
12/8/2023Wells Fargo & CompanyInitiated CoverageOverweight$58.00Low
11/7/2023CitigroupInitiated CoverageBuy$42.00Low
10/24/2023Cantor FitzgeraldInitiated CoverageOverweight$50.00Low
8/28/2023MizuhoReiterated RatingBuy ➝ Buy$60.00Low
8/17/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$42.00 ➝ $38.00Low
8/14/2023MizuhoBoost TargetBuy ➝ Buy$50.00 ➝ $60.00Low
7/18/2023The Goldman Sachs GroupBoost TargetBuy$29.00 ➝ $50.00Low
7/18/2023Raymond JamesBoost TargetOutperform$29.00 ➝ $46.00Low
7/18/2023BTIG ResearchBoost Target$32.00 ➝ $42.00Low
7/18/2023MizuhoBoost Target$29.00 ➝ $50.00Low
7/17/2023Jefferies Financial GroupDowngradeBuy ➝ Hold$24.00 ➝ $33.00Low
5/8/2023MizuhoBoost Target$23.00 ➝ $29.00Low
4/19/2023Evercore ISIInitiated CoverageOutperform$40.00Low
4/13/2023SVB SecuritiesBoost TargetOutperform$25.00 ➝ $27.00Low
3/7/2023Raymond JamesBoost TargetOutperform$17.00 ➝ $29.00Low
3/7/2023The Goldman Sachs GroupBoost TargetBuy$20.00 ➝ $28.00Low
3/7/2023JPMorgan Chase & Co.Boost TargetOverweight$18.00 ➝ $23.00Low
3/7/2023Bank of AmericaBoost Target$15.00 ➝ $18.00Low
2/6/2023CowenInitiated CoverageOutperformLow
2/6/2023CowenInitiated CoverageOutperformLow
1/23/2023SVB LeerinkLower TargetOutperform$23.00 ➝ $19.00Low
11/18/2022JPMorgan Chase & Co.Lower TargetOverweight$20.00 ➝ $19.00Low
8/24/2022MizuhoLower TargetBuy$25.00 ➝ $23.00Low
7/26/2022SVB LeerinkBoost TargetOutperform$27.00 ➝ $30.00Low
6/15/2022The Goldman Sachs GroupBoost TargetBuy ➝ Buy$19.00 ➝ $21.00Low
5/24/2022The Goldman Sachs GroupLower TargetBuy$24.00 ➝ $19.00High
3/16/2022HC WainwrightLower TargetBuy$24.00 ➝ $22.00High
3/11/2022JPMorgan Chase & Co.Lower TargetOverweight$21.00 ➝ $18.00High
3/4/2022SVB LeerinkBoost TargetOutperform$24.00 ➝ $25.00Medium
1/31/2022HC WainwrightReiterated RatingBuy$24.00Low
12/28/2021HC WainwrightLower TargetBuy$88.00 ➝ $24.00Medium
12/27/2021SVB LeerinkLower TargetOutperform$66.00 ➝ $24.00N/A
12/27/2021MizuhoLower TargetBuy$86.00 ➝ $25.00N/A
11/19/2021SVB LeerinkLower TargetOutperform$68.00 ➝ $66.00High
11/3/2021MizuhoReiterated RatingBuyMedium
10/25/2021HC WainwrightReiterated RatingBuyHigh
10/13/2021MizuhoInitiated CoverageBuy$86.00Medium
10/4/2021SVB LeerinkBoost TargetOutperform$66.00 ➝ $68.00Medium
9/10/2021Bank of AmericaUpgradeNeutral ➝ Buy$75.00Low
8/6/2021SVB LeerinkLower TargetOutperform$71.00 ➝ $66.00Medium
7/16/2021SVB LeerinkReiterated RatingOutperformLow
5/20/2021UBS GroupInitiated CoverageBuy$80.00Low
5/7/2021The Goldman Sachs GroupLower TargetBuy$92.00 ➝ $80.00High
4/11/2021SVB LeerinkReiterated RatingBuyLow
3/23/2021Jefferies Financial GroupReiterated RatingBuy$79.00Medium
3/23/2021SVB LeerinkBoost TargetOutperform$67.00 ➝ $75.00High
3/22/2021The Goldman Sachs GroupBoost TargetPositive ➝ Buy$83.00 ➝ $91.00High
3/20/2021MizuhoInitiated CoverageBuy$86.00High
3/4/2021MizuhoBoost TargetBuy$56.00 ➝ $86.00Low
2/22/2021JPMorgan Chase & Co.Initiated CoverageOverweightMedium
2/9/2021The Goldman Sachs GroupReiterated RatingBuy$83.00 ➝ $83.00Low
1/11/2021HC WainwrightBoost TargetBuy$64.00 ➝ $87.00High
12/14/2020BTIG ResearchBoost TargetBuy$49.00 ➝ $91.00High
12/10/2020HC WainwrightBoost TargetBuy$53.00 ➝ $64.00Low
12/4/2020SVB LeerinkBoost TargetOutperform$39.00 ➝ $44.00Medium
12/2/2020MizuhoBoost TargetBuy$51.00 ➝ $56.00High
11/5/2020Piper SandlerBoost TargetOverweight$50.00 ➝ $60.00Low
10/12/2020HC WainwrightBoost TargetBuy$50.00 ➝ $53.00Low
10/6/2020BMO Capital MarketsBoost TargetOutperform$44.00 ➝ $49.00High
9/30/2020The Goldman Sachs GroupBoost Target$43.00 ➝ $52.00High
8/12/2020HC WainwrightReiterated RatingBuy$50.00High
6/25/2020Bank of AmericaInitiated CoverageNeutral$38.00High
6/11/2020HC WainwrightReiterated RatingBuy$50.00Medium
5/19/2020BTIG ResearchInitiated CoverageBuy$49.00Low
5/14/2020SVB LeerinkLower TargetOutperform$41.00 ➝ $39.00High
4/13/2020HC WainwrightInitiated CoverageBuy$50.00High
3/3/2020JPMorgan Chase & Co.Boost TargetOverweight$38.00 ➝ $43.00Low
2/18/2020MizuhoInitiated CoverageBuy$51.00High
1/7/2020Raymond JamesBoost Target$36.00 ➝ $40.00Low
12/3/2019UBS GroupInitiated CoverageReduceHigh
10/18/2019Piper Sandler CompaniesDropped CoverageBuy$50.00N/A
7/26/2019Raymond JamesInitiated CoverageOutperform ➝ Outperform$36.00High
7/22/2019SVB LeerinkInitiated CoverageOutperform ➝ Outperform$34.00High
7/22/2019Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$38.00High
7/22/2019JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$38.00High
7/22/2019Piper Sandler CompaniesInitiated CoverageOverweight ➝ Overweight$50.00High
7/22/2019The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$42.00High
7/22/2019BMO Capital MarketsInitiated CoverageOutperform ➝ Outperform$49.00High
(Data available from 4/14/2019 forward)

News Sentiment Rating

0.51 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 10 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
9/17/2023
  • 5 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/17/2023
  • 3 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/16/2023
  • 8 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/16/2023
  • 8 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/15/2024
  • 19 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/14/2024
  • 23 very positive mentions
  • 37 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
3/15/2024
  • 8 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/14/2024

Current Sentiment

  • 8 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
BridgeBio Pharma logo
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
Read More

Today's Range

Now: $26.83
Low: $26.37
High: $28.13

50 Day Range

MA: $31.39
Low: $26.83
High: $39.23

52 Week Range

Now: $26.83
Low: $12.75
High: $44.32

Volume

1,888,372 shs

Average Volume

1,446,853 shs

Market Capitalization

$4.72 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.03

Frequently Asked Questions

What sell-side analysts currently cover shares of BridgeBio Pharma?

The following Wall Street sell-side analysts have issued research reports on BridgeBio Pharma in the last year: BMO Capital Markets, BTIG Research, Cantor Fitzgerald, Citigroup Inc., Evercore ISI, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Mizuho, Raymond James, The Goldman Sachs Group, Inc., and Wells Fargo & Company.
View the latest analyst ratings for BBIO.

What is the current price target for BridgeBio Pharma?

12 Wall Street analysts have set twelve-month price targets for BridgeBio Pharma in the last year. Their average twelve-month price target is $47.17, suggesting a possible upside of 75.8%. Cantor Fitzgerald has the highest price target set, predicting BBIO will reach $70.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $33.00 for BridgeBio Pharma in the next year.
View the latest price targets for BBIO.

What is the current consensus analyst rating for BridgeBio Pharma?

BridgeBio Pharma currently has 2 hold ratings and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for BBIO.

What other companies compete with BridgeBio Pharma?

How do I contact BridgeBio Pharma's investor relations team?

BridgeBio Pharma's physical mailing address is 421 Kipling Street, Palo Alto CA, 94301. The company's listed phone number is (650) 391-9740. The official website for BridgeBio Pharma is bridgebio.com. Learn More about contacing BridgeBio Pharma investor relations.